Thorne Research Announces Clinical Study to Assess Nicotinamide Riboside on Brain NAD+ in College Football Players
“Thorne Research and ChromaDex Corp. (OTCQX: CDXC) announced today a research endeavor with Mayo Clinic and the University of Minnesota Clinical and Translational Science Institute, regarding a planned clinical study to assess the effect of Nicotinamide Riboside (NR) on brain NAD+ in college football players.
The randomized, placebo controlled, double-blind study will enroll healthy male collegiate football linemen, not having a history of more than 3 concussions. Participants will take either 750 mg per day of Nicotinamide Riboside (NR) or placebo for 84 days. Pre- and post-intervention evaluations include physical assessment, blood tests for safety and toxicity monitoring, blood tests for biomarkers, neurologic testing, quality of life questionnaires, and real time measurement of brain NAD, using 31P MRS.
The primary outcome of the study is to measure the change in brain NAD+ levels over 3 months. The study is expected to begin in May 2016 with final data collected by March 2017.”
Read the article: https://www.thorne.com/news/thorne-research-announces-clinical-study-nicotinamide-riboside-college-football-players?utm_source=Jeff+-+PR+on+NR+%284%2F15%2F2016%29&utm_campaign=PR+%2F+NiaCel+Callout+%284%2F15%2F2016%29&utm_medium=email